Total Payments
$3,546
2024 Payments
$244.41
Companies
15
Transactions
50
Medicare Patients
6,746
Medicare Billing
$5.6M
Payment Breakdown by Category
Food & Beverage$2,332 (65.8%)
Travel$734.29 (20.7%)
Other$479.12 (13.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,332 | 41 | 65.8% |
| Travel and Lodging | $734.29 | 1 | 20.7% |
| Current or prospective ownership or investment interest | $479.12 | 4 | 13.5% |
| Unspecified | $0 | 4 | 0.0% |
Payments by Type
General
$3,546
46 transactions
Ownership
$0
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $1,328 | 5 | $0 (2019) |
| Alcon Vision LLC | $677.52 | 8 | $0 (2021) |
| US Retina LLC | $479.12 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $245.81 | 3 | $0 (2019) |
| EyePoint Pharmaceuticals US, Inc. | $201.62 | 8 | $0 (2022) |
| Shire North American Group Inc | $125.83 | 1 | $0 (2018) |
| Astellas Pharma US Inc | $124.99 | 1 | $0 (2024) |
| Genentech USA, Inc. | $122.37 | 3 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $89.79 | 5 | $0 (2024) |
| Alimera Sciences, Inc. | $37.86 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $244.41 | 8 | Astellas Pharma US Inc ($124.99) |
| 2023 | $126.26 | 5 | Genentech USA, Inc. ($77.28) |
| 2022 | $351.26 | 7 | US Retina LLC ($243.13) |
| 2021 | $479.91 | 12 | US Retina LLC ($235.99) |
| 2020 | $223.89 | 3 | Alcon Vision LLC ($199.59) |
| 2019 | $1,976 | 13 | Mallinckrodt Enterprises LLC ($1,328) |
| 2018 | $144.27 | 2 | Shire North American Group Inc ($125.83) |
All Payment Transactions
50 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/01/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/01/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Ophthalmology | ||||||
| 06/28/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $20.20 | General |
| Category: Ophthalmology | ||||||
| 06/21/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $26.65 | General |
| Category: Immunology and Ophthalmology | ||||||
| 04/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Ophthalmology | ||||||
| 01/29/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Ophthalmology | ||||||
| 2024 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 10/23/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $16.21 | General |
| Category: Ophthalmology | ||||||
| 04/18/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $18.67 | General |
| Category: Ophthalmology | ||||||
| 04/13/2023 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: EYE CARE | ||||||
| 03/14/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $77.28 | General |
| Category: Immunology and Ophthalmology | ||||||
| 2023 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 10/24/2022 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: RETINA | ||||||
| 10/13/2022 | Coherus Biosciences Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: Ophthalmology | ||||||
| 04/18/2022 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $49.76 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 04/13/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $211.40 | General |
| 04/12/2022 | US Retina LLC | — | Current or prospective ownership or investment interest | Cash or cash equivalent | $31.73 | General |
| 02/17/2022 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $22.02 | General |
| Category: Ophthalmology | ||||||
| 2022 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/08/2021 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 09/30/2021 | EyePoint Pharmaceuticals US, Inc. | YUTIQ (Drug) | Food and Beverage | In-kind items and services | $55.09 | General |
| Category: Chronic Non-infectious Posterior Segment Uveitis | ||||||
| 08/11/2021 | Bausch & Lomb, a division of Bausch Health US, LLC | VISUDYNE (Drug) | Food and Beverage | In-kind items and services | $22.76 | General |
| Category: Ophthalmology | ||||||
| 07/19/2021 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Postoperative Inflammation | ||||||
| 05/21/2021 | EyePoint Pharmaceuticals US, Inc. | DEXYCU (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Postoperative Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,531 | 16,037 | $4.4M | $1.9M |
| 2022 | 21 | 1,903 | 8,277 | $3.8M | $1.6M |
| 2021 | 22 | 1,786 | 5,843 | $3.0M | $1.3M |
| 2020 | 17 | 1,526 | 3,603 | $1.7M | $723,736 |
Total Patients
6,746
Total Services
33,760
Medicare Billing
$5.6M
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 127 | 1,554 | $2.3M | $1.1M | 46.0% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 28 | 9,360 | $468,000 | $272,299 | 58.2% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 43 | 1,088 | $565,760 | $197,592 | 34.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 224 | 1,150 | $526,752 | $113,910 | 21.6% |
| 92134 | Imaging of retina | Office | 2023 | 426 | 1,579 | $142,614 | $47,134 | 33.0% |
| J3490 | Unclassified drugs | Office | 2023 | 12 | 24 | $73,200 | $43,848 | 59.9% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 13 | 273 | $68,250 | $43,025 | 63.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 158 | 174 | $34,452 | $16,343 | 47.4% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 151 | 161 | $30,666 | $14,749 | 48.1% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 50 | 216 | $29,160 | $14,736 | 50.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 78 | 78 | $23,712 | $9,529 | 40.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 68 | 99 | $13,104 | $6,310 | 48.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 43 | 85 | $11,223 | $5,134 | 45.7% |
| 92242 | Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye | Office | 2023 | 18 | 41 | $8,526 | $4,222 | 49.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 22 | 25 | $6,649 | $3,217 | 48.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $6,786 | $2,854 | 42.1% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 20 | 48 | $7,421 | $1,417 | 19.1% |
| 92250 | Photography of the retina | Office | 2023 | 32 | 64 | $4,500 | $830.22 | 18.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 129 | 1,340 | $2.0M | $963,240 | 47.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 48 | 909 | $472,680 | $199,673 | 42.2% |
| J3590 | Unclassified biologics | Office | 2022 | 25 | 59 | $177,000 | $107,583 | 60.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 251 | 1,106 | $481,440 | $102,879 | 21.4% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2022 | 21 | 343 | $85,750 | $54,179 | 63.2% |
| 92134 | Imaging of retina | Office | 2022 | 519 | 1,654 | $149,862 | $47,114 | 31.4% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 12 | 1,500 | $75,000 | $44,762 | 59.7% |
About Dr. Shelly Lee, MD
Dr. Shelly Lee, MD is a Ophthalmology healthcare provider based in Spokane, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1285817288.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shelly Lee, MD has received a total of $3,546 in payments from pharmaceutical and medical device companies, with $244.41 received in 2024. These payments were reported across 50 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,332).
As a Medicare-enrolled provider, Lee has provided services to 6,746 Medicare beneficiaries, totaling 33,760 services with total Medicare billing of $5.6M. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Spokane, WA
- Active Since 12/12/2007
- Last Updated 08/01/2024
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1285817288
Products in Payments
- ACTHAR (Biological) $1,328
- Constellation (Device) $677.52
- YUTIQ (Drug) $174.23
- XIIDRA (Drug) $125.83
- Izervay (Drug) $124.99
- Vabysmo (Drug) $103.93
- Syfovre (Drug) $89.79
- DEXYCU (Drug) $65.25
- OZURDEX (Drug) $31.60
- VISUDYNE (Drug) $22.76
- XIPERE (Drug) $22.02
- Cimerli (Biological) $18.85
- Lucentis (Biological) $18.44
- EYLEA (Biological) $18.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Spokane
Dr. Barbara Smit, M.d, M.D
Ophthalmology — Payments: $157,604
Ophthalmology $157,604
Robert Wirthlin, M.d, M.D
Ophthalmology — Payments: $97,188
Ophthalmology $97,188
Jessica Weinstein, M.d, M.D
Ophthalmology — Payments: $10,020
Ophthalmology $10,020
Dr. Gary Fillmore, M.d, M.D
Ophthalmology — Payments: $6,469
Ophthalmology $6,469
Dr. Steven Day, M.d, M.D
Ophthalmology — Payments: $2,955
Ophthalmology $2,955
Heidi Eiseman, M.d, M.D
Ophthalmology — Payments: $2,197
Ophthalmology $2,197